Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A complex seeding of multiple metastases in clear cell renal cell carcinoma

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE113206 | GEO | 2022/04/04

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

A complex seeding of multiple metastases in clear cell renal cell carcinoma (CGH)

Project description:Tumor heterogeneity resulting from clonal evolution is a frequent feature in clear cell renal cell carcinoma (ccRCC) and could play a role in metastatic dissemination. However, the dynamics of metastatic evolution is not completely elucidated and could follow a complex seeding process. Using a unique experimental design with a rare matched primary-metastatic case prior to any medical treatment, we retraced the lineage of metastatic clones that showed a complex, multiple, polyphyletic seeding of two functionally interdependent subclonal populations originating from the primary tumor, in the direction of all metastatic sites.

2022-04-04 | GSE113205 | GEO

A complex seeding of multiple metastases in clear cell renal cell carcinoma (expression)

2022-04-04 | GSE113204 | GEO

A complex seeding of multiple metastases in clear cell renal cell carcinoma

Project description:A complex seeding of multiple metastases in clear cell renal cell carcinoma

| PRJNA450416 | ENA

A complex seeding of multiple metastases in clear cell renal cell carcinoma (CGH)

Project description:A complex seeding of multiple metastases in clear cell renal cell carcinoma (CGH)

| PRJNA450420 | ENA

A complex seeding of multiple metastases in clear cell renal cell carcinoma (expression)

Project description:A complex seeding of multiple metastases in clear cell renal cell carcinoma (expression)

| PRJNA450421 | ENA

Expression and methylation data of human clear cell renal cell carcinoma

Project description:This SuperSeries is composed of the SubSeries listed below.

2017-11-04 | GSE89649 | GEO

Expression data from pulmonary metastases of clear-cell renal cell carcinoma

Project description:The understanding of metastatic spread is limited and molecular mechanisms causing particular characteristics of metastasis, like varying dormancy periods of Mets originating from the same primary tumor entity or the differing number of Mets in patients with the same primary tumor, are largely unknown. Knowing the molecular fundamentals of these phenomena would support the prognosis of patients´ outcome and facilitate the decision for an appropriate therapy regime. We analyzed the transcriptome-wide expression profiles of 20 pulmonary metastases of renal cell carcinoma in order to identify expression patterns associated with two important prognostic factors in RCC: the disease-free interval after nephrectomy (DFI) and the number of Mets per patient. Keywords: comparison of pulmonary metastases from patients with different clinical characteristics metastases manifested early or late after nephrectomy (DFI less than or equal to 9 vs. greater than or equal to 60 months) metastases derived from patients with only few or multiple pulmonary metastases (less than or equal to 8 vs. greater than or equal to 16)

2009-01-13 | E-GEOD-14378 | biostudies-arrayexpress

Stereotactic Radiosurgery for Multiple Brain Metastases From Renal-Cell Carcinoma.

Project description:BackgroundBrain metastases (BM) pose a significant problem in patients with metastatic renal-cell carcinoma (mRCC). Local and systemic therapies including stereotactic radiosurgery (SRS) are rapidly evolving, necessitating reassessments of outcomes for modern patient management.Patients and methodsThe mRCC patients with BM treated with SRS were reviewed. Patient demographics, clinical history, and SRS treatment parameters were identified.ResultsAmong 268 patients with mRCC treated between 2006 and 2015, 38 patients were identified with BM. A total of 243 BM were treated with SRS with 1 to 26 BMs treated per SRS session (median, 2 BMs). The median (range) BM size was 0.6 (0.2-3.1) cm and median (range) SRS treatment dose was 18 (12-24) Gy. Treated BM local control rates at 1 and 2 years were 91.8% (95% confidence interval, 85.7-95.4) and 86.1% (95% confidence interval, 77.1-91.7), respectively. BM control declined for larger tumors. Survival after 1-year was 57.5% (95% CI 40.2-71.4) for all patients. Survival was not statistically different between patients with < 5 BM versus ≥ 5 BM. Survival was prognostic based on International Metastatic Renal Cell Carcinoma Database (IMDC) risk groups in patients with < 5 BM. Two patients experienced grade 3 radiation necrosis requiring surgical intervention.ConclusionSRS is effective in controlling BM in patients with mRCC. Over half of treated patients survive past a year, and no differences in survival were noted in patients with > 5 metastases. Prognostic risk categories based on systemic disease (IMDC) are predictive of survival in this BM population, with limited rates of symptomatic radiation necrosis.

| S-EPMC6563340 | biostudies-literature

Integrated profiling of microRNAs and mRNAs: microRNAs located on Xq27.3 associate with clear cell renal cell carcinoma

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2013-09-29 | E-GEOD-24952 | biostudies-arrayexpress

Expression data from pulmonary metastases of clear-cell renal cell carcinoma

2009-01-13 | GSE14378 | GEO